745 related articles for article (PubMed ID: 23511301)
21. Low frequency of cytomegalovirus (CMV) disease despite high prevalence of CMV viraemia in patients with advanced HIV infection: a clinical and immunological 48-week follow-up study.
Albasanz-Puig A; Suanzes P; Esperalba J; Fernández C; Sellarès-Nadal J; Torrella A; Planas B; Segura A; Burgos J; Ribera E; Cañas-Ruano E; García JN; Navarro J; Curran A; Len Ó; Falcó V
HIV Med; 2021 Sep; 22(8):682-689. PubMed ID: 33998115
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
[TBL] [Abstract][Full Text] [Related]
23. Cytomegalovirus infection in HIV-infected versus non-infected infants and HIV disease progression in Cytomegalovirus infected versus non infected infants early treated with cART in the ANRS 12140-Pediacam study in Cameroon.
Kfutwah AK; Ngoupo PA; Sofeu CL; Ndongo FA; Guemkam G; Ndiang ST; Owona F; Penda IC; Tchendjou P; Rouzioux C; Warszawski J; Faye A; Tejiokem MC
BMC Infect Dis; 2017 Mar; 17(1):224. PubMed ID: 28335737
[TBL] [Abstract][Full Text] [Related]
24. [The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].
Cartón JA; Maradona JA; de Oña M; Asensi V; Melón S; García-Alcalde ML; Rodríguez-Junquera M; Moreno-Torrico A; de Zárraga M
Med Clin (Barc); 1999 Sep; 113(6):205-9. PubMed ID: 10472608
[TBL] [Abstract][Full Text] [Related]
25. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
[TBL] [Abstract][Full Text] [Related]
26. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
27. Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa.
Fielding K; Koba A; Grant AD; Charalambous S; Day J; Spak C; Wald A; Huang ML; Corey L; Churchyard GJ
PLoS One; 2011; 6(10):e25571. PubMed ID: 22022413
[TBL] [Abstract][Full Text] [Related]
28. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R
J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879
[TBL] [Abstract][Full Text] [Related]
29. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.
Zoufaly A; Stellbrink HJ; Heiden MA; Kollan C; Hoffmann C; van Lunzen J; Hamouda O;
J Infect Dis; 2009 Jul; 200(1):79-87. PubMed ID: 19476437
[TBL] [Abstract][Full Text] [Related]
30. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
31. Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy.
Levi LI; Sharma S; Schleiss MR; Furrer H; Nixon DE; Blackstad M; Hernandez-Alvarado N; Dwyer DE; Borges AH; Lane HC; Lundgren J; Neaton JD; Molina JM;
AIDS; 2022 Jul; 36(9):1265-1272. PubMed ID: 35442221
[TBL] [Abstract][Full Text] [Related]
32. Clinical relevance of the plasma load of cytomegalovirus in patients infected with HIV--a survival analysis.
Aramă V; Mihăilescu R; Rădulescu M; Aramă SŞ; Streinu-Cercel A; Youle M;
J Med Virol; 2014 Nov; 86(11):1821-7. PubMed ID: 25087866
[TBL] [Abstract][Full Text] [Related]
33. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.
Wohl DA; Kendall MA; Andersen J; Crumpacker C; Spector SA; Feinberg J; Alston-Smith B; Owens S; Chafey S; Marco M; Maxwell S; Lurain N; Jabs D; Benson C; Keiser P; Jacobson MA;
HIV Clin Trials; 2009; 10(3):143-52. PubMed ID: 19632953
[TBL] [Abstract][Full Text] [Related]
34. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting.
Manosuthi W; Chaovavanich A; Tansuphaswadikul S; Prasithsirikul W; Inthong Y; Chottanapund S; Sittibusaya C; Moolasart V; Termvises P; Sungkanuparph S
J Infect; 2007 Nov; 55(5):464-9. PubMed ID: 17714788
[TBL] [Abstract][Full Text] [Related]
35. Quantitation of cytomegalovirus (CMV) DNA by real-time PCR for occurrence of CMV disease in HIV-infected patients receiving highly active antiretroviral therapy.
Gourlain K; Salmon D; Gault E; Leport C; Katlama C; Matheron S; Costagliola D; Mazeron MC; Fillet AM; ;
J Med Virol; 2003 Mar; 69(3):401-7. PubMed ID: 12526052
[TBL] [Abstract][Full Text] [Related]
36. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
37. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
38. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
39. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
[TBL] [Abstract][Full Text] [Related]
40. Survival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern Vietnam.
Cuong do D; Thorson A; Sönnerborg A; Hoa NP; Chuc NT; Phuc HD; Larsson M
Scand J Infect Dis; 2012 Mar; 44(3):201-8. PubMed ID: 22122590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
